Hikma Pharmaceuticals announces launch of argatroban injection

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year.

The London-based pharmaceutical firm's argatroban is used for the prevention of disease and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Thrombosis is the formation of a blood clot inside the blood vessel obstructing the flow of blood through the circulatory system. HIT is due to the administration of various forms of heparin, an anticoagulant, and is caused by the formation of abnormal antibodies that activate platelets.

Argatroban will also work as an anticoagulant in preventing the clotting of the blood in adults at risk of HIT undergoing coronary angioplasty, a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in coronary heart disease.

"Hikma is pleased to be bringing argatroban injection to market," Chief Executive Officer of Hikma, Samih Darwazah, said in a statement.

"Argatroban will expand our injectables product line and help to differentiate our product portfolio in the US."

Argatroban injection made approximately $105m in sales for the 12 months ending October 2012, according to IMS Health.

Hikma will be selling the argatroban injection in 100mg/ml vials and was developed through the company's partnership with the speciality pharmaceutical company, Exela Pharma Sciences.

Shares for Hikma, which has a market capitalisation of £1,488.17m, reported a 0.26% drop in shares to 755.00p at 10:15 Thursday.

RD

Recommended

3 emerging market dividend stocks to buy now
Share tips

3 emerging market dividend stocks to buy now

Professional investor Omar Negyal of the JPMorgan Global Emerging Markets Income Trust picks three of his favourite emerging market stocks for income …
4 Oct 2022
Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
The best British tech stocks from a thriving sector
Share tips

The best British tech stocks from a thriving sector

Move over, Silicon Valley. Over the past two decades the UK has become one of the main global hubs for tech start-ups. Matthew Partridge explains why,…
29 Sep 2022
These 3 top value stocks offer
Share tips

These 3 top value stocks offer

Professional investor Adam Rackley of Cape Wrath Capital highlights three overlooked value stocks to buy.
29 Sep 2022

Most Popular

Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
Should you fix your mortgage? Here are the best rates available now
Mortgages

Should you fix your mortgage? Here are the best rates available now

Rising interest rates look set to spring a nasty surprise on millions of homeowners next year. You need to take steps today to protect yourself from a…
30 Sep 2022
Why everyone is over-reacting to the mini-Budget
Budget

Why everyone is over-reacting to the mini-Budget

Most analyses of the chancellor’s mini-Budget speech have failed to grasp its purpose and significance, says Max King
29 Sep 2022